Abstract: Since terbinafi ne was introduced on the world market 17 years ago, it has become the leading antifungal for the treatment of superfi cial fungal infections, aided by unique pharmacologic and microbiologic profi les. This article reviews mode of action, antimycotic spectrum and disposition profi le of terbinafi ne. It examines the data, accumulated over 15 years, on the comparative effi cacy of terbinafi ne (vs griseofulvin, itraconazole, fl uconazole) in the management of the infections for which it is primarily indicated (eg, dermatophytoses) and provides a brief discussion on its use for the treatment of non-dermatophyte infections. Finally, the available data on the newest topical and systemic formulations are introduced.
Introduction
In 2008, oral terbinafi ne reached the 12-year mark in the United States (US) and 17 years on the world market. Since its launch, terbinafi ne has garnered the top slot among topical antifungals and the oral formulation is estimated to have captured nearly 80% of the greater than US$1.5 billion worldwide onychomycosis market (although it makes up only a minority of prescriptions written for children). 1, 2 Terbinafi ne remains the only commercially available orally available allylamine and shares the topical allylamine/benzylamine market with naftifi ne, butenafi ne and amorolfi ne. In recent years several new formulations have been added to the portfolio of this antimycotic including a pediatric oral granule approved by the US Food and Drug Administration in September of 2007 and a single-dose, fi lm-forming topical solution that is now available over the counter in a number non-US markets.
This article will review the accumulated data on the mycology and pharmacology of terbinafi ne including its mode of action, antimycotic spectrum, disposition profi le and therapeutic effi cacy. The primary focus will surround dermatophytoses with a brief discussion on the role, to date, of terbinafi ne in non-dermatophyte infections.
Clinical mycology
Discovered in 1983, terbinafi ne is a member of the allylamine class of antifungals. It differs from its parent compound, naftifi ne, by the presence of a tert-butyl acetylene substitution of the phenyl ring on the side chain of the molecule. This substitution confers an increase in oral effi cacy and an additional 10 to 100 times the in vitro activity of naftifi ne. 3, 4 Terbinafi ne inhibits fungal growth by disrupting sterol biosynthesis. It abrogates the formation of ergosterol by inhibiting squalene epoxidase, the catalytic enzyme responsible for converting squalene to 2,3-oxidosqualene (an ergosterol precursor). The resultant defi ciency in ergosterol compromises cell wall integrity and contributes to impaired growth and/or death of the pathogen. [5] [6] [7] Notably, the biosynthesis of cholesterol in higher order eukaryotes similarly relies on the activity of squalene epoxidase; however, terbinafi ne demonstrates a markedly lower binding affi nity for the mammalian enzyme. In vitro, the minimum concentration of terbinafi ne required to inhibit 95% of squalene epoxidase activity (IC 95 ) is two to three orders of magnitude greater for the mammalian enzyme (300 μM) than for enzymes isolated from pathogenic yeast (0.6-2.1 μM). 7 While the majority of clinical terbinafi ne use is observed with infections caused by dermatophytes, the susceptibility of numerous organisms including pathogenic yeast, dematiaceae, thermally dimorphic fungi and hyaline hyphomycetes has been evaluated. [8] [9] [10] [11] [12] [13] [14] [15] [16] Although the nature of the assays employed precludes direct comparison of minimum inhibitory concentrations (MICs) between studies (ie, some were performed prior to standardization of a reference method by the Clinical and Laboratory Standards Institute (CLSI), 17 some universal trends are repeated throughout. Namely, terbinafi ne demonstrates the greatest activity against species within the Trichophyton, Microsporum, and Epidermophyton genera followed by the dematiaceae, the fi lamentous fungi and a few selected pathogenic yeast.
The terbinafi ne MICs observed against the dermatophytes are typically several orders of magnitude lower than those reported for other fungi. [18] [19] [20] [21] [22] [23] This heightened susceptibility is refl ected by an MIC that is an order of magnitude lower than IC 95 for sterol biosynthesis. 6 Given that dermatophyte growth can be fully inhibited despite only partial inhibition of sterol synthesis, the activity of terbinafi ne is likely accounted for by other processes including the intracellular accumulation of squalene. 3 In contrast, the MIC to IC 95 ratio for several species of fermentative yeast equals or exceeds one. 6 Compared with dermatophytes, these organisms have adapted to survive under anaerobic growth conditions which are characterized by low ergosterol and high squalene concentrations. 6 Reasonably, it is expected that such organisms would be less susceptible to the effects of a squalene epoxidase inhibitor.
The MICs reported for terbinafi ne against various dermatophytes are typically comparable to or lower than those of other antifungals active against these organisms, namely the triazoles, imidazioles and griseofulvin. 24 However, a direct comparison of MICs between therapeutic agents needs to be considered in the context of achievable concentrations at the site of infection. No signifi cant differences in terbinafi ne susceptibilities exist between US and non-US isolates of selected Trichophyton and Microsporum species. 25 Further, the putative increase in resistance to azole antifungals observed with the "heartier" arthroconidia of the dermatophytes has not been observed with terbinafi ne. Both arthroconidia and microconidia of selected Trichophyton species demonstrate the same susceptibility profi le to terbinafi ne in vitro. 26 In addition to diminished susceptibility, non-dermatophyte species of fungi demonstrate resistance mechanisms not observed in the dermatophytes. Under the selective pressure of terbinafi ne exposure, an increase in the expression of energy-dependent effl ux transporters can be observed in yeast; 27 however, the expression level of orthologous transporters remains unchanged in dermatophytes. 28 Similarly, fi lamentous fungi can upregulate the expression of an enzyme that catalyzes the breakdown of terbinafi ne 29 but this has not been reported for dermatophytes.
Overall, an extremely low rate of spontaneous mutation conferring resistance of dermatophytes to terbinafi ne exists in vitro. 30 Nonetheless, reduced susceptibility to terbinafi ne has been observed in clinical dermatophyte isolates. These appear to arise from clones harboring one of two described sequence variations in the squalene epoxidase gene. 31, 32 As the reported mutations do not appear to impact fungal growth in the absence of terbinafi ne, 33 they likely signal changes to the terbinafi ne binding domain and ultimately binding affi nity of the drug for the protein. 34 While spontaneous resistance is rare, increasing reports describe cross-resistance developing between other antifungals and terbinafine. Under the selective pressure of echinocandin exposure in vitro, the upregulation of effl ux transporters in yeast also reduced susceptibility to terbinafi ne. 35 Similarly, azole "pre-exposure" in yeast can diminish susceptibility of the organisms to terbinafi ne. [36] [37] [38] Notably, the aforementioned mechanisms of cross-resistance have not been reported for dermatophytes, in vitro or in vivo, after protracted imidazole treatment. [36] [37] [38] Of potentially signifi cant clinical relevance is the activity of terbinafi ne when used in combination with other antifungals for the management of invasive mycoses. Against Aspergillus fumigatus, indifference was primarily observed when terbinafi ne was combined with amphotericin B. Similarly, terbinafi ne did not improve the activity of fl uconazole or itrazonazole against A. fumigatus; however, the triazoles demonstrated synergism when added to terbinafi ne. 39 Against fl uconazole-resistant yeast, synergy with fl uconazole and itraconazole was observed in a fraction of isolates, Candida glabrata Ͼ Candida tropicalis, Ͼ Candida kreusi. 40, 41 In these pathogenic yeast antagonism has also been observed among these antifungals. 41 Against ocular isolates of Fusarium, the combination of amphotericin B and terbinafi ne was synergistic, while the combination of terbinafi ne and
Terbinafi ne in dermatophytoses triazoles demonstrated indifference. 42 The ultimate utility of terbinafi ne in the management of invasive infections will be determined as more experience is obtained utilizing this agent as adjunct therapy.
Clinical pharmacology (Tables 1 and 2)
Terbinafi ne is effi ciently absorbed following oral administration (bioavailability approx. 70%) and this does not appear to be affected by feeding status. 51, 52 Over the range of clinically relevant doses (125-750 mg) terbinafi ne demonstrates a linear absorption profi le with total body exposure increasing in direct proportion to dose. 53 The rate of absorption does not appear to differ substantially between children and adults. However, the extent of absorption as refl ected by maximum plasma concentrations is markedly lower in children when doses are normalized per kilogram of body weight. 43 Following topical administration to normal skin, cream-and gel-based terbinafi ne formulations attain concentrations ranging from 746 to 949 ng/cm 2 . 48, 54 Maximum stratum corneum concentrations increase by 15% with 7 days of application; however, the area under the plasma concentration vs time curve (AUC) can increase by as much as 40% over 1 week. 54 Notably, concentrations obtained in the horny layer of patients with an active infection can be up to an order of magnitude lower than that observed in healthy individuals. 55 While topical preparations are well absorbed into the stratum corneum, the resultant systemic exposure is several orders of magnitude lower than observed after oral terbinafi ne administration (Tables 1 and 2) .
Terbinafine is extensively distributed with estimates of apparent distribution volume approaching 20 L/kg. 53, 56 This relatively large volume of distribution results from the drugs high degree of lipophilicity, extensive protein binding profi le and ability to concentrate in adipose and keratin rich tissue. 56, 57 At steady-state, concentrations observed in sebum, stratum corneum and hair exceed those observed in the plasma by as much as an order of magnitude. Although lower in the stratum corneum of hyperkeratotic tissue, terbinafi ne concentrations remain elevated following the discontinuation of oral therapy and persist in excess of 1 month after stopping treatment. 58 At least seven cytochromes P450 (CYP) appear to be responsible for metabolizing terbinafi ne into more than 15 metabolites. 59 In adults, the N-demethyl and carboxybutyl metabolites constitute the largest fraction of the metabolites observed. Maximum circulating concentrations and total body exposure are comparable or in excess of those observed with the parent compound. Notably, the circulating half-life for the carboxy metabolites were twice as long as that of terbinafi ne. 46 Although the metabolites lack an appreciable antifungal activity, they may contribute to the drug interactions and/or side effects observed following administration. 51, 60 Given the polyfunctional nature of terbinafine as a substrate for the CYP450, the magnitude of potential drug interactions would be predicted to be low as compared with other drugs. [61] [62] [63] However, this is not the case for interactions mediated by CYP2D6. Terbinafi ne exhibits potent inhibition of this enzyme in vitro (apparent inhibitor rate constant (k i ) approx. 30 nM) and correspondingly marked reduction in the metabolism of the CYP2D6 substrate dextromethorphan in vivo. 60, 64 Importantly, the activity of CYP2D6 may not return to normal for months after the completion of a prolonged course of therapy. 64 Clinically, terbinafi ne is demonstrated to interact with concurrently administered CYP2D6 substrates including amitriptyline, nortriptyline, desipramine, and b Corresponding peak tissue concentrations: hair, 2.4 μg/g; stratum corneum, 14.4 μg/g; sebum, 56.1 μg/g. Abbreviations: T max , time at maximum plasma concentration; C max , maximum plasma concentration; AUC, area under the plasma concentration vs time curve; Cl/F, apparent oral clearance; Vss/F, steady-state volume of distribution; t 1/2α , alpha-phase half-life; t 1/2β , beta-phase half-life, t 1/2γ , gamma-phase or terminal half-life.
venlafaxine. [65] [66] [67] [68] Other drugs harboring the potential to interact with terbinafi ne include perphenazine, metoprolol, encainide and propafenone. 69 For drugs that are not substrates of CYP2D6 (eg, anticoagulants, corticosteroids, oral contraceptives, tolbutamide, cyclosporine, midazolam, digoxin and terfenadine) terbinafi ne has only a modest or minimal affect on their metabolism. [70] [71] [72] [73] [74] However, as a substrate of the cytochromes P450, the pharmacokinetics of terbinafi ne are altered with the concurrent administration of several agents (eg, cimetidine, terfenadine, rifampin). 70, 75 The clearance of terbinafi ne is triphasic with the terminal elimination half-life approximating 100 hours after a single dose and 22 days with durations of therapy spanning several months. 44, 76 Approximately 80% of terbinafi ne's metabolites are excreted by the kidney with the remaining fraction eliminated in the feces. 44 This protracted rate of elimination accounts for the magnitude of accumulation observed with terbinafi ne after repeated dosing and the persistence in plasma and tissues long after discontinuation of the drug. 47 While this confers a distinct advantage to the allylamine permitting shorter courses of therapy, it poses a unique disadvantage for patients experiencing drug-related adverse events.
Therapeutic use
Terbinafine is indicated for use in the management of cutaneous dermatophytoses (eg, tinea corporis, tinea cruris and tinea pedis), onychomycosis and most recently tinea capitis. In addition, terbinafi ne use has been explored in a number of superfi cial and systemic mycoses involving pathogens other than the dermatophytes. The results of openlabel and randomized trials exploring the utility of terbinafi ne in various infections is detailed in the following sections.
Cutaneous dermatophytoses
Dermatophyte infections of the glabrous skin, groin and feet can be caused by any of a number of dermatophyte species. 77 While these infections typically respond to topical antifungals, oral therapy is often indicated when the lesions are widespread or chronic in nature. 78 Terbinafi ne applied topically as a 1% cream, gel or solution demonstrates utility in the management of both tinea corporis and tinea cruris. 79 The application of terbinafi ne once-daily for 7 to 14 days resulted in mycological cure rates ranging from 84% to 94%, clinical cure rates ranging from 75% to 84% and overall effi cacy rates ranging from 65% to 83%; [80] [81] [82] [83] [84] [85] [86] The observed treatment response with topical terbinafi ne is signifi cantly greater than reported for placebo wherein clinical, mycological and complete cure rates range from 8% to 22%. 81, 83 Topically applied terbinafi ne also demonstrated statistically greater mycological response rates than a 2-week course of 2% ketoconazole cream, 80 whereas clinical response rates were comparable to a 0.6% gel containing the garlic-derived, sulfuric compound ajoene. 84 Following oral administration for the treatment of tinea corporis and tinea cruris, clinical and mycological cure rates observed with terbinafi ne have ranged from 71% to 100% and 78% to 100%, respectively. 78, [87] [88] [89] No signifi cant differences in mycological or clinical cure rates were observed between terbinafi ne and griseofulvin in these studies; [87] [88] [89] however, higher relapse rates were observed with griseofulvin. 88, 89 Tinea imbricata, a variant of tinea corporis found predominantly in tropical countries, manifests as concentric rings of papular plaques that are chronic in nature and relatively recalcitrant to antifungal therapy. In a single randomized, controlled trial 4 weeks of treatment with terbinafi ne demonstrated higher overall effi cacy rates (100%) and lower relapse rates (16%) as compared with itraconazole (89% effi cacy, 75% relapse). 90 Tinea pedis is a dermatophyte infection of the foot that generally takes one of three forms: 1) interdigital infections characterized by cracking and fi ssuring of the skin in the webbing between the toes, 2) acute vesicular infections which present with erythema, bullous eruptions and bacterial Terbinafi ne in dermatophytoses super-infections and 3) a chronic form of infection with scaling that covers the entire foot typically referred to as "dry" or "moccasin" type tinea pedis. 91 The nature and extent of infection often determines whether oral therapy is required or whether symptomatic relief can be obtained with topical therapy. 92 Although topical terbinafi ne formulations in excess of 1% have been investigated, superfi cial treatment of tinea pedis typically relies on 5 to 7 days of application with the 1% cream, gel or solution (as described above for infections of the skin and groin). Mycologic cure rates are comparable irrespective of formulation, ranging from 82% to 97% with overall effi cacy rates of 64% to 86%. Response rates are signifi cantly greater than observed with the vehicle alone wherein mycologic cure and overall effi cacy range from 22% to 37% and 4% to 26%, respectively. 83, [93] [94] [95] [96] Mycological cure rates, after 1 week of treatment, are also comparable to or greater than those observed after 4 weeks of treatment with topical azole preparations. [97] [98] [99] Despite the advantage of a strong effi cacy profi le with the application of terbinafi ne for one week, efforts to simplify topical administration, decrease treatment duration and improve compliance has lead to the development of a polymeric fi lm-forming solution (FFS) designed as a "one-time" dose. The acrylate/cellulose/triglyceride based formulation leaves a nearly invisible, highly-concentrated fi lm on the skin after the carrier solvent (ethanol) has evaporated. This fi lm remains on the site of infection nearly 6 times longer than other topical preparations and results in stratum corneum concentrations that are sustained above the MIC in excess of 2 weeks after application.
50,100 FFS concentrations as high as 10% have been evaluated; however, mycological cure rates (80%-84%) and overall effi cacy (61%-70%) 6 weeks after application did not appear to demonstrate dose-dependence. 100 Consequently, the currently marketed formulation contains 1% terbinafi ne. In a study examining slightly longer-term follow-up, mycological cure rates were observed in 72% of those treated. Notably, the duration of infection prior to treatment did not appear to infl uence the likelihood of mycological cure. When participants were re-evaluated at 3 months, 12.5% of those individuals considered mycologically cured at 6 weeks demonstrated positive cultures, comparable to the rates observed with other topical terbinafi ne formulations. 101 For more refractory (eg, hyperkeratotic) infections of the foot, effi cacy rates comparable to those described above can be observed with topical treatment; however, this may require protracted treatment durations (ie, several months). 55 In these cases, oral therapy has emerged as a reliable alternative. Orally administered terbinafi ne can be highly effective in the management of tinea pedis with overall effi cacy rates exceeding 90% depending on the nature of infection and the regimen used. The majority of investigations have examined the effi cacy of orally administered terbinafi ne at daily doses of 250 mg (either divided or once daily). Effi cacy rates after 6 weeks of treatment ranged from 59% to 75%, increasing to 65% to 88% 12 weeks after the end of therapy. 102, 103 This is compared with placebo and griseofulvin where effi cacy rates were 0% and 27%, respectively at the end of treatment and 0% and 45%, respectively, 2 weeks post treatment. 102, 103 With shorter courses of oral treatment (250 mg daily × 2 weeks), mycological and clinical cure rates are markedly less impressive (23%-28% and 8%-43%, respectively). However, when followed out for 6 to 16 weeks, mycological cure rates (78%-86%) and clinical effi cacy (71%-94%) improve dramatically suggesting utility with shorter treatment durations of terbinafi ne. 104, 105 Cure rates observed with terbinafi ne were comparable to those observed with itraconazole (100 mg/day); however, long-term follow-up suggested that terbinafi ne was slightly superior to 4 weeks of itraconazole treatment and signifi cantly superior to 2 weeks of treatment with the triazole. 104, 105 Data from a single study each suggest that reducing (125 mg/day) or increasing (500 mg/day) the dose of terbinafi ne may not substantially alter cure rates compared traditional dosing with 250 mg/day.
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Onychomycosis
Approximately one-half of all nail problems are accounted for by onychomycosis, a fungal infection wherein the nails become discolored, thickened and prone to peeling or splitting. 106 Dermatophytes are principally responsible for infections of the toenail, whereas over 50% of fi ngernail infections can be caused by non-dermatophyte species. 107, 108 Of the commercially available oral antifungals, griseofulvin, itraconazole and terbinafine are most commonly used for the management of onychomycosis. Efficacy rates and treatment durations vary although treatment with the latter agents typically requires shorter courses than does the former. Irrespective, the majority of studies described below document cure rates at 12 months or beyond (earlier for fi ngernails) to account for the protracted growth rate of nails and the extended time-frames over which drug remains in the affected nails.
Since its approval, scores of studies have evaluated numerous terbinafi ne dosing regimens for the treatment of onychomycosis. With the administration of daily 250 mg doses, mycologic and clinical response rates observed in toenails ranged from 72% to 92% and 45% to 77%, respectively. [109] [110] [111] [112] [113] Notably, there was little difference in both clinical and mycological response rates whether patients were treated for 12, 18 or 24 weeks. 109, [111] [112] [113] Infections of the fi ngernail demonstrated comparable response rates ranging from 71% to 100%. 109, 111, 114 When non-dermatophyte pathogens are considered in subgroup analyses, response rates approximate 40% for infections with Candida and greater than 90% when treating Scopulariopsis brevicaulis. [115] [116] [117] The combination of daily terbinafi ne doses (250 mg) with chemical or mechanical removal of the nail offers little to no additional increase in effi cacy over terbinafi ne alone. 118, 119 Similarly, only limited increases in effi cacy are observed when daily oral therapy is combined with adjunctive therapy including once-weekly topical amorolfi ne or once-daily topical ciclopirox. [120] [121] [122] [123] In each study topical therapy appeared to confer slight improvements in response; however, limited sample sizes restrict their signifi cance and superiority over terbinafi ne alone could not be determined.
Intermittent terbinafi ne dosing has also been explored for the management of onychomycosis. When the standard regimen of 250 mg once daily was compared to intermittent dosing administered at 350 mg daily for 2 weeks followed by 2 weeks "off " for the management of subungual onychomycosis, both mycological (56%-58% vs 43%-50%) and complete cure (26%-30% vs 20%-24%) favored traditional dosing; however, only the latter was statistically signifi cant. 124 When compared with 500 mg administered daily for 1 week (followed by 3 weeks off) for the treatment of distal subungual onychomycosis, traditional dosing again proved superior to intermittent dosing. Mycological cure of the target toenail (71% vs 59%); clinical cure of the target toenail (45% vs 29%); complete cure of the target toenail (40% vs 28%); and complete cure of all 10 toenails (25% vs 15%) were all statistically greater with standard dosing. 125 No signifi cant differences in complete cure have been observed based on the number of pulses administered; however, a clear trend is noted with response rates increasing steadily from one to four pulses. 126 As noted with traditional dosing, higher cure rates were observed for fi ngernails treated with pulsedosing as compared with toe nails. Mycological and clinical cure rates were 89% and 72% for dermatophytes, albeit lower (67%) for infections caused by yeast. 127 As expected based on the comparative data generated from traditional dosing trials, the combination of pulse therapy with ancillary topical therapy does not substantially improve outcome over treatment with terbinafi ne alone. [126] [127] [128] In two comparative trials, terbinafine (250 mg/day) was significantly superior to griseofulvin (500 mg/day). Mycological cure rates were significantly higher with terbinafi ne (84%-92% vs 45%-63%), time to mycological cure significantly shorter (73 vs 93 days) and clinical cure significantly higher (76% vs 39%) as compared with griseofulvin. 129, 130 However, the exclusion of nondermatophyte pathogens in one study and the administration of sub-clinical griseofulvin doses in both studies likely resulted in an overestimate of terbinafi ne's superiority. In a single trial employing the recommended dose of griseofulvin (1000 mg daily) mycological response was similar between terbinafi ne and griseofulvin (88% vs 82%, respectively); however, clinical response at the end of study was greater with terbinafi ne (81% vs 62%). Not surprisingly time to negative mycologic cultures was shorter for terbinafi ne (130 days vs 172 days). 131 In three studies, traditional dose itraconazole (200 mg/day) was compared with traditional dose terbinafi ne (250 mg/day). In only one investigation where infections were solely restricted to those caused by dermatophytes did mycological cure rates favor terbinafi ne (81%-92% vs 63%-67%). In the remaining investigations no difference in mycological cure rates were observed between the allylamine and the triazole. [132] [133] [134] The remainder of studies comparing the two agents examined pulse-dosing of itraconazole. In the treatment of distal and lateral subungual onychomycosis restricted to dermatophytes, no appreciable difference was observed between itraconazole (400 mg/day one week "on" three weeks "off ") and terbinafi ne (mycological cure rates: 75%-90% vs 76%-87%, clinical cure rates 53%-82% vs 50%-79%). [135] [136] [137] [138] Not surprisingly, itraconazole demonstrated superior cure rates among the non-dermatophyte moulds (62% vs 44%) and Candida species (92% vs 40%). 138 These studies are contradicted by a large multi-national trial wherein mycological cure rates at 18 months were significantly greater with terbinafine (76%-80%) than observed with pulse-dose itraconazole (38%-49%). 139 In selected subpopulations, complete cure rates observed after 4 years remained superior in the terbinafi ne arm (24%-78%) compared with those receiving itraconazole (24%-28%) as did mycological cure (46% vs 13%). 140, 141 Finally, two investigations compare daily terbinafi ne with once weekly fluconazole (150 mg). Clinical cure rates (21%-38% vs 67%-81%), mycological cure rates (31%-51% vs 75-89%) and overall effi cacy (31% vs 62%) were inferior in fl uconazole treated patients. 135, 142 Despite reasonable effi cacy rates, the results of numerous trials indicate that a substantial fraction of onychomycosis patients treated with terbinafi ne remain uncured at the end Terbinafi ne in dermatophytoses of treatment. Consequently several investigations have attempted to address whether additional intrinsic or extrinsic factors infl uence treatment response. Although the majority of these investigations were not adequately powered to defi nitively determine an association between selected covariates and treatment failure, several trends could be observed. The studies suggested that a higher fraction of patients 1) receiving lower terbinafi ne doses (125 mg vs 250 mg), 2) with distal and lateral subungual onychomycosis, 3) with big toenail involvement, or 4) with positive mycology 3 months into treatment remain uncured at the time of follow-up. [143] [144] [145] The link between other factors such as demographic characteristics, the rate of nail growth, the species of infecting pathogen, the extent and duration of disease at the time of presentation and the number of nails involved remain unclear.
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Tinea capitis
Ringworm of the scalp is a dermatophyte infection commonly seen among preschool and school-aged children. It is one of the few dermatophyte infections that does not adequately respond to topical therapy, often requiring 6 to 8 weeks of oral antifungal treatment. 147 Griseofulvin remains the gold standard in the management of this infection, but treatment failures are common and it is not unusual for children to remain on therapy for extended durations. 148 Several studies have examined the role of terbinafi ne in the treatment of tinea capitis; however, results need to be considered in the context of the geographic origin of the study participants given that the primary causative organisms and, thus response rates, are expected to vary between countries. [149] [150] [151] The majority of these studies examine a weight-based dosing scheme with 62.5 mg of terbinafi ne administered to children under 20 kg, 125 mg administered to children between 20 and 40 kg and an adult dose of 250 mg administered to children over 40 kg.
With the administration of terbinafi ne for one week, Trichophyton infections are effectively treated in 56% of children. 152, 153 Effi cacy rates ranged from 69% to 86% after 2 weeks of treatment, averaged 65% with 4 weeks of treatment and ranged from 80% to 100% after 6 weeks of therapy. 44, [152] [153] [154] [155] Corresponding mycological cure rates observed after 1, 2, 4 and 6 weeks of treatment were 60%, 76%, 72% and Ͼ90%, respectively. 44, 152, 154 By contrast, infections with Microsporum are less responsive to terbinafi ne. Response rates as low as 15% are observed with 1 to 2 weeks of therapy. 153 However, extended durations of treatment and/or doubling of the dose appeared to improve the likelihood of effi cacy in children harboring Microsporum and clinical and mycological response rates begin to approximate those observed for Trichophyton. 153, [156] [157] [158] In comparative trials, terbinafi ne, when used for durations of 4 weeks, appeared to be as effective as griseofulvin administered for slightly longer intervals (8 weeks). Clinical and mycological cure rates ranged from 64% to 93% and 70% to 93%, respectively for terbinafi ne and 67% to 80% and 72% to 88%, respectively for griseofulvin. [159] [160] [161] As above, the exception lies with infections caused by Microsporum where griseofulvin appears to be superior to terbinafi ne even when the allylamine is administered for 12 weeks. [160] [161] [162] Pulse regimens wherein the standard dose or double the standard dose of terbinafi ne is administered daily for 1 week (followed by 3 weeks off) do not appear to confer any advantage or disadvantage in the treatment of Microsporum infections over standard regimens. 163 By contrast, terbinafi ne appeared to be slightly more effective than both itraconazole and fl uconazole in treating tinea capitis. 164 It should be noted that in a number of the aforementioned studies, the griseofulvin doses employed (as low as 6 mg/kg) were markedly lower than those recommended for use in clinical practice. Consequently, the studies may have underestimated the effi cacy of griseofulvin.
A single publication is available detailing the results of two randomized-controlled trials that compared 6 weeks of treatment with the recently marketed terbinafi ne oral granule formulation (5-8 mg/kg daily) with griseofulvin (10-20 mg/kg daily) for the management of tinea capitis. The new formulation is designed to be sprinkled on foods thereby improving the reliability with which the drug can be administered to young children (Ͼ4 years of age). In these investigations, the complete cure rate observed with terbinafi ne was superior to griseofulvin in one trial (46% vs 34%) but not the other (44% vs 43%). Similarly mycological cure rates were signifi cantly higher in trial 1 (62% vs 50%) but not in trial 2 (61% vs 60%). In affi rmation of the results conferred in previously conducted trials, subgroup analyses in these trials revealed that terbinafi ne was signifi cantly better than griseofulvin when children were infected with Trichophyton tonsurans whereas griseofulvin proved superior for the treatment of infections with Microsporum canis. 165 This multi-national study also reported greater effi cacy among US vs non-US infections which was likely accounted for by the higher fraction of children in the US that are infected with T. tonsurans.
Non-dermatophyte infections
Although not within the scope of this review, we would be remiss not to point out the increasing utilization of terbinafi ne, alone and in combination, for the management of non-dermatophyte infections. Despite its higher MIC to pathogenic yeast, topically administered terbinafi ne appeared effective for the management of tinea versicolor, 166 and orally administered terbinafi ne (250 mg twice daily) has been used successfully for the treatment of cutaneous candidiasis. 167 Given, however, that the majority of superfi cial Candida infections will respond to topical antifungals, the role of terbinafi ne in these infections remains unclear. A brief summary of additional non-dermatophyte infections wherein terbinafi ne has been utilized is provided in Table 3 .
Adverse effects
Terbinafine has been extensively used with a relatively low incidence of reported adverse drug reactions. Clinical trials evaluating the efficacy of orally administered terbinafine in both children and adults have noted adverse event rates in as high as 52%; however, less than 10% were attributed to the drug. 165, [182] [183] [184] Most terbinafine related adverse events are mild or moderate and include gastrointestinal complaints (eg, nausea, abdominal pain, vomiting, diarrhea), cutaneous eruptions, weight gain, appetite changes, headaches, and vertigo. 43, 152, 165, 185, 186 Those adverse reactions involving the gastrointestinal system and skin are most commonly associated with discontinuation of therapy, 165, 186 with the risk of discontinuation estimated at 3.4%. 187 Serious adverse drug reactions, most commonly involving the liver and the hematologic system, are only rarely reported with terbinafi ne use (0.04%). 188 Hepatotoxicity ranging from mild transaminitis to fulminant liver failure has been reported as a consequence of oral terbinafi ne use. It is estimated that 2.2% of patients treated with terbinafi ne will experience changes in their liver function tests. 187 The onset typically occurs after 3 weeks of therapy and resolution can take as long as 3 months after discontinuation of the drug. While the majority of cases resolve following discontinuation of terbinafi ne, reports are available detailing patients that have progressed to liver transplantation and death. 189, 190 Notably, hepatic fi ndings are not restricted to adults. An FDA review of the recently marketed terbinafine oral granule identifi ed two cases, among 1042 children treated, of elevated transaminases leading to discontinuation of the drug. 191 Terbinafi ne-induced acute autoimmune hepatitis has also been reported in a patient infected with hepatitis B virus. 192, 193 Blood dyscrasias including leucopenia, agranulocytosis, neutropenia and pancytopenia represent the other primary group of severe adverse drug reactions reported with terbinafi ne use. Most cases occur between weeks 4 to 5 of therapy and resolve within a week after stopping the medication. One fatality has been reported in a 79-year-old female who developed septic shock while being treated for terbinafi ne induced agranulocytosis. 194 Among children receiving the new granule formulation, leucopenia and/or neutropenia was observed in 1.8% (19/1042) of the children treated. 191 Severe dermatologic eruptions including toxic epidermolysis, acute generalized exanthematous pustulosis, and Steven's Johnson syndrome have also been associated with terbinafi ne use. 195 Recently, reports have also linked dermatomyositis and subacute cutaneous systemic lupus erythematosus to terbinafi ne. 196, 197 In one patient, a skin eruption presenting 4 weeks after the onset of therapy and occurring with the triad of fever, hepatic dysfunction and lymphadenopathy led investigators to conclude the presence of hypersensitivity syndrome. Resolution was experienced within 6 weeks of discontinuing the drug. [198] [199] [200] [201] [202] [203] An adverse effect unique to terbinafine is altered taste perception. Although numerous case reports have been published, there exist no reliable estimates of this side effect in patients taking terbinafi ne. [204] [205] [206] [207] [208] [209] [210] Ageusia has taken up to 6 weeks to resolve, and was reported in association with loss of smell and discoloration of the tongue, in one patient each. 208, 210 Possible risk factors for developing terbinafi ne associated taste loss include an age greater than 65 years and a body mass index less than 21 kg/m 2 . 211 Notably, a singular trial comparing terbinafi ne with griseofulvin for the treatment of tinea capitis, reported a change of eating habits in 4.7% and 5.5% of children, respectively. Whether, however, this was due to changes in taste perception is unknown. 165 Of note, fewer patients receiving terbinafi ne pulse therapy as compared with traditional dosing experience elevations in liver enzymes or taste disturbances; however, the overall percentage of patients discontinuing therapy for adverse events was comparable between dosing strategies. 124 While only a few reports exist, ocular side effects have been observed with oral terbinafi ne use. [212] [213] [214] Bilateral anterior optic neuropathy with decreased vision and optic disc edema was reported in a patient 2 weeks after starting terbinafi ne (500 mg/day). 214 After discontinuing the medication his vision improved. Anterior uveitis was reported in a second patient with acquired immune defi ciency syndrome after 12 days of therapy. As in the previous case, symptoms resolved with discontinuation of terbinafi ne. 213 Among patients treated with topical terbinafi ne preparations, adverse events are primarily restricted to mild to moderate local skin reaction which may occur in as many as 6% of patients.
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Conclusions
Terbinafi ne is among the most commonly used antifungal agents for the treatment of dermatophyte infections of the skin and nails. The success experienced by this drug can, in large part, be attributed to its favorable mycologic and pharmacokinetic profi les. Terbinafi ne possesses many of the characteristics required of a drug used for infections where clinical resolution is largely dependent on the slow turnover of infected tissue, namely, excellent penetration at the site of infection and sustained fungicidal activity for extended durations after the discontinuation of therapy. Numerous clinical trials corroborate the suitability of terbinafi ne for the treatment of dermatophytoses with effi cacy rates comparable to or greater than existing antifungals despite shorter treatment durations. While the role of terbinafi ne use in systemic mycoses has been limited to date, the agent may eventually fi nd utility as an adjunctive agent in the management of recalcitrant infections. Although terbinafi ne is likely to remain the fi rst-line agent for a number of dermatophyte infections, prescribers should remain cognizant of the infrequent but severe adverse reactions that have been observed (eg, agranulocytosis, hepatotoxicity) and the potential for signifi cant drug-drug interactions with medications that rely on CYP2D6 as a primary route of metabolism.
